BioSpace News Archive

ICER recommended two out of three outpatient treatments for COVID-19 in today’s market, singling out molnupiravir as having inadequate evidence that it is better than symptomatic care.

Flagship Pioneering has partnered with Novo Nordisk to build a portfolio of potential treatments for cardiometabolic and rare diseases.

BioSpace spoke with industry experts to find out the differences between working in pharma and biotech and how to know if a pharma company is right for you.

The revised PDUFA action date for miglustat is August 29, 2022, while the new date for cipaglucosidase alfa is October 29, 2022. Amicus expects the agency to approve the applications together.

Jacqueline Shea will take over as the new CEO and announced plans to discontinue its Phase III Innovate trial to prioritize its heterologous booster strategy for COVID-19.

Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple Phase 2 and Phase 3 study presentations on seladelpar, the first delpar currently in development for the treatment of PBC, will be delivered during Digestive Disease Week® (DDW) May 21 – 24.

Opus Genetics announced the appointment of Jennifer Hunt as Chief Development Officer.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2022.

PharmAbcine Inc. announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to participate at Jefferies Global Healthcare Conference over June 8-10, 2022 in New York, NY.